References
- American Psychiatric Association., American Psychiatric Association. DSM-5 task force. Diagnostic and statistical manual of mental disorders : dSM-5. (5th ed.) (WA) D.C: American Psychiatric Association; 2013. doi: 10.1176/appi.books.9780890425596
- Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012 Jul;9(3):490–499. doi: 10.1007/s13311-012-0135-8
- Faraone SV, Banaschewski T, Coghill D, et al. The world federation of ADHD International consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789–818. doi: 10.1016/j.neubiorev.2021.01.022
- Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National comorbidity survey replication. Am J Psychiatry. 2006 Apr;163(4):716–723. doi: 10.1176/ajp.2006.163.4.716
- Sibley MH, Arnold LE, Swanson JM, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Am J Psychiatry. 2022 Feb;179(2):142–151. doi: 10.1176/appi.ajp.2021.21010032
- Cabral MDI, Liu S, Soares N. Attention-deficit/hyperactivity disorder: diagnostic criteria, epidemiology, risk factors and evaluation in youth. Transl Pediatr. 2020 Feb;9(Suppl 1):S104–S113. doi: 10.21037/tp.2019.09.08
- van Lieshout M, Luman M, Twisk JW, et al. A 6-year follow-up of a large European cohort of children with attention-deficit/hyperactivity disorder-combined subtype: outcomes in late adolescence and young adulthood. Eur Child Adolesc Psychiatry. 2016 Sep;25(9):1007–1017. doi: 10.1007/s00787-016-0820-y
- Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012 Sep 4;10(1):99. doi: 10.1186/1741-7015-10-99
- Fletcher JM. The effects of childhood ADHD on adult labor market outcomes. Health Econ. 2014 Feb;23(2):159–181. doi: 10.1002/hec.2907
- Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):990–1002 e2. doi: 10.1016/j.jaac.2012.07.008
- Kosheleff AR, Mason O, Jain R, et al. Functional impairments associated with ADHD in adulthood and the impact of pharmacological treatment. J Atten Disord. 2023 May;27(7):669–697. doi: 10.1177/10870547231158572
- National Institute for Health Care Excellence Attention deficit hyperactivity disorder: diagnosis and management. [cited 2023 Sep 16]. Available from: https://www.nice.org.uk/guidance/ng87.
- Canadian ADHD Practice Guidelines. [cited 2023 Sep 17]. Available from: https://adhdlearn.caddra.ca/wp-content/uploads/2022/08/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf.
- Australian Evidence-Based Clinical Practice Guideline For Attention Deficit Hyperactivity Disorder. [cited 2023 Jul 1]. Available from: https://adhdguideline.aadpa.com.au/download/
- Childress AC. Novel formulations of ADHD medications: stimulant selection and management. Focus (Am Psychiatr Publ). 2021 Jan;19(1):31–38. doi: 10.1176/appi.focus.20200032
- Highlights of Prescribing Information Strattera® (atomoxetine) capsules for oral use. [cited 2023 Sep 17]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021411.
- Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010 Jan;122(1):184–191. doi: 10.3810/pgm.2010.01.2112
- Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543–1569. doi: 10.2147/NDT.S65721
- Highlights of Prescribing Information Concerta (methylphenidate HCl) Extended-Release Tablets, CII. [cited 2023 Jul 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021121s044lbl.pdf
- Highlights of Prescribing Information Vyvanse® (lisdexamfetamine dimesylate) capsules, for oral use, CII. [cited 2023 Sep 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021977s046,208510s003lbl.pdf.
- Highlights of Prescribing Information QelbreeTM (viloxazine extended-release capsules). [cited 2023 Sep 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211964s003lbl.pdf
- Surman C, Vaudreuil C, Boland H, et al. L-Threonic Acid Magnesium Salt supplementation in ADHD: an open-label Pilot study. J Diet Suppl. 2021;18(2):119–131. doi: 10.1080/19390211.2020.1731044
- Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/Hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022 Sep 1;42(5):429–439. doi: 10.1097/JCP.0000000000001575
- A Controlled Study of Solriamfetol for ADHD in Adults. [cited 2023 Jul 17]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04839562
- Cingulate Press Release Jul 11, 2023 Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD. [cited 2023 Jul 16]. Available from: https://www.cingulate.com/news-releases/news-release-details/cingulate-announces-positive-top-line-results-phase-3-adult
- Surman C, Vaudreuil C, Boland H, et al. L-Threonic Acid Magnesium Salt supplementation in ADHD: an open-label pilot study. J Diet Suppl. 2020 Mar;12:1–13.
- Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of Viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300. doi: 10.2147/JEP.S256586
- NDA 211964 Viloxazine Extended-Release Capsules Integrated Review. [cited 2023 Jul 16]. Available from: https://www.fda.gov/media/148484/download
- Wang Z, Kosheleff AR, Adeojo LW, et al. Impact of a high-fat meal and sprinkled administration on the bioavailability and pharmacokinetics of viloxazine extended-release capsules (Qelbree(tm)) in Healthy adult subjects. Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):69–79. doi: 10.1007/s13318-021-00729-6
- Gahr M. Caffeine, the most frequently consumed psychostimulant: a narrative review article. Fortschr Neurol Psychiatr. 2020 May;88(5):318–330. doi: 10.1055/a-0985-4236
- Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017 Apr;15(3):434–443. doi: 10.2174/1570159X14666161228122115
- Wang Z, Kosheleff AR, Adeojo LW, et al. Impact of paroxetine, a strong CYP2D6 inhibitor, on SPN-812 (viloxazine extended-release) pharmacokinetics in Healthy adults. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1365–1374. doi: 10.1002/cpdd.948
- Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and methylphenidate in Healthy adults. Clin Drug Investig. 2021 Feb;41(2):149–159. doi: 10.1007/s40261-020-00992-6
- Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and lisdexamfetamine in Healthy adults. J Clin Psychopharmacol. 2021 Mar 1;41(2):155–162. doi: 10.1097/JCP.0000000000001361
- Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: a historical overview and Current status. CNS Drugs. 2021 Jun;35(6):643–653. doi: 10.1007/s40263-021-00825-w
- Brosnan RD, Busby AM, Holland RP. Cases of overdosage with viloxazine hydrochloride (vivalan). J Int Med Res. 1976;4(2):83–85. doi: 10.1177/030006057600400201
- Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/Hyperactivity disorder in school-age children. Clin Ther. 2020 Aug;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021
- Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021 Apr;43(4):684–700. doi: 10.1016/j.clinthera.2021.01.027
- Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020 Jan;24(2):348–358. doi: 10.1177/1087054719836159
- Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/Hyperactivity disorder. J Clin Psychopharmacol. 2021 Jul 1;41(4):370–380. doi: 10.1097/JCP.0000000000001404
- Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021 Mar 16;51(2):43–64. doi: 10.1016/j.clinthera.2021.01.027
- Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind,Placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/Hyperactivity disorder. CNS Drugs. 2022 Aug;36(8):897–915. doi: 10.1007/s40263-022-00938-w
- Spencer TJ, Adler LA, Meihua Q, et al. Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord. 2010 Jul;14(1):57–68. doi: 10.1177/1087054709347435
- Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007 Jul;4(7):28–37.
- Roth RM, Lance CE, Isquith PK, et al. Confirmatory factor analysis of the behavior rating inventory of Executive function-adult version in healthy adults and application to attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2013 Aug;28(5):425–434. doi: 10.1093/arclin/act031
- Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092–1097. doi: 10.1001/archinte.166.10.1092
- Cutler AJ, Adler LA. Qelbree® (viloxazine extended-release capsules): final results of the long-term, phase 3, open-label extension trial in adults with ADHD. American Society of Clinical Psychopharmacology Annual Meeting; 30 May -2 June; Miami (FL); 2023.
- Price MZ, Price RL. Extended-release viloxazine compared with atomoxetine for attention deficit hyperactivity disorder. CNS Drugs. 2023 Jul 10. doi: 10.1007/s40263-023-01035-2
- FDA Adverse Events Reporting System (FAERS) Public Dashboard. [cited 2023 Jul 23]. Available from: https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis
- Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009 Feb;29(1):44–50. doi: 10.1097/JCP.0b013e318192e4a0
- Supernus Announces Fourth Quarter and Full Year 2022 Financial Results. [cited 2023 Jul 23]. Available from: https://ir.supernus.com/news-releases/news-release-details/supernus-announces-fourth-quarter-and-full-year-2022-financial
- Iwanami A, Saito K, Fujiwara M, et al. Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/Hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2020 Apr 14;81(3). doi: 10.4088/JCP.19m12979
- Puts NA, Ryan M, Oeltzschner G, et al. Reduced striatal GABA in unmedicated children with ADHD at 7T. Psychiatry Res Neuroimaging. 2020 Jul 30;301:111082. doi: 10.1016/j.pscychresns.2020.111082
- Aevi Genomic Medicine : Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD. [cited 2023 Jul 29]. Available from: https://www.marketscreener.com/quote/stock/AEVI-GENOMIC-MEDICINE-IN-32526460/news/Aevi-Genomic-Medicine-Announces-Top-Line-Results-from-Placebo-Controlled-ASCEND-Trial-Parts-A-B-27815598/
- Childress A, Sallee FR. Pozanicline for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Nov;23(11):1585–1593. doi: 10.1517/13543784.2014.956078
- Manor I, Newcorn JH, Faraone SV, et al. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. Postgrad Med. 2013 Jul;125(4):181–190. doi: 10.3810/pgm.2013.07.2689
- Alcobra abandons troubled lead drug after phase 3 failure. [cited 2023 Jul 29]. Available from: https://www.fiercebiotech.com/biotech/alcobra-abandons-troubled-lead-drug-after-phase-iii-failure
- Wigal SB, Hopkins SC, Koblan KS, et al. Efficacy and safety of Dasotraline in children with ADHD: a laboratory classroom study. J Atten Disord. 2020 Jan;24(2):192–204. doi: 10.1177/1087054719864644
- Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the treatment of attention-deficit/Hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology. 2015 Nov;40(12):2745–2752. doi: 10.1038/npp.2015.124
- Sunovion Discontinues Dasotraline Program. [cited 2023 Jul 29]. Available from: https://news.sunovion.com/press-releases/press-releases-details/2020/Sunovion-Discontinues-Dasotraline-Program/default.aspx
- Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010 Jun;71(6):754–763. doi: 10.4088/JCP.08m04902pur
- Botter PA. A double blind comparison of viloxazine and amitryptyline in involutional and endogenous depression. Acta Psychiatr Belg. 1979 Mar;79(2):198–209.